Prime Medicine (PRME) Competitors $3.34 -0.25 (-6.95%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends PRME vs. TARS, IMCR, BCRX, NVAX, VIR, MESO, IMTX, CRGX, CGEM, and LENZShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Tarsus Pharmaceuticals (TARS), Immunocore (IMCR), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Vir Biotechnology (VIR), Mesoblast (MESO), Immatics (IMTX), CARGO Therapeutics (CRGX), Cullinan Therapeutics (CGEM), and LENZ Therapeutics (LENZ). These companies are all part of the "biological products, except diagnostic" industry. Prime Medicine vs. Tarsus Pharmaceuticals Immunocore BioCryst Pharmaceuticals Novavax Vir Biotechnology Mesoblast Immatics CARGO Therapeutics Cullinan Therapeutics LENZ Therapeutics Tarsus Pharmaceuticals (NASDAQ:TARS) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Is TARS or PRME more profitable? Prime Medicine has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Tarsus Pharmaceuticals' return on equity of -55.86% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-103.64% -55.86% -39.28% Prime Medicine N/A -107.87%-74.97% Do analysts rate TARS or PRME? Tarsus Pharmaceuticals currently has a consensus price target of $54.20, suggesting a potential upside of 20.90%. Prime Medicine has a consensus price target of $13.25, suggesting a potential upside of 296.11%. Given Prime Medicine's higher possible upside, analysts clearly believe Prime Medicine is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Prime Medicine 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Which has stronger earnings & valuation, TARS or PRME? Tarsus Pharmaceuticals has higher revenue and earnings than Prime Medicine. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$17.45M98.21-$135.89M-$3.81-11.77Prime MedicineN/AN/A-$198.13M-$2.05-1.63 Does the MarketBeat Community believe in TARS or PRME? Tarsus Pharmaceuticals received 26 more outperform votes than Prime Medicine when rated by MarketBeat users. However, 65.52% of users gave Prime Medicine an outperform vote while only 65.22% of users gave Tarsus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTarsus PharmaceuticalsOutperform Votes4565.22% Underperform Votes2434.78% Prime MedicineOutperform Votes1965.52% Underperform Votes1034.48% Do insiders & institutionals believe in TARS or PRME? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 23.5% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, TARS or PRME? Tarsus Pharmaceuticals has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Prime Medicine has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Does the media refer more to TARS or PRME? In the previous week, Prime Medicine had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 20 mentions for Prime Medicine and 18 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.42 beat Prime Medicine's score of 0.19 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTarsus Pharmaceuticals and Prime Medicine tied by winning 9 of the 18 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$438.73M$2.94B$5.12B$19.76BDividend YieldN/A1.81%5.18%3.50%P/E Ratio-1.6320.4872.8137.06Price / SalesN/A224.491,250.2017.77Price / CashN/A176.6640.7021.54Price / Book2.324.056.454.64Net Income-$198.13M-$42.42M$119.73M$982.94M7 Day Performance-18.41%-10.63%-5.13%-2.12%1 Month Performance-11.97%-5.81%-2.71%-0.39%1 Year Performance-49.32%24.19%31.08%23.34% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.047 of 5 stars$3.35-7.0%$13.25+296.1%-45.6%$438.73MN/A-1.63234Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageTARSTarsus Pharmaceuticals1.7501 of 5 stars$49.08-0.7%N/A+152.8%$1.87B$83.37M-10.9650Analyst ForecastAnalyst RevisionNews CoverageIMCRImmunocore2.9264 of 5 stars$34.64-0.1%N/A-32.6%$1.73B$296.31M-36.46497Gap DownBCRXBioCryst Pharmaceuticals4.2114 of 5 stars$8.19+5.3%N/A+36.8%$1.70B$331.41M-13.43530Short Interest ↓NVAXNovavax3.7314 of 5 stars$9.01+1.1%N/A+25.6%$1.44B$983.71M-3.261,543Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageVIRVir Biotechnology3.2556 of 5 stars$9.87+2.8%N/A-16.9%$1.36B$62.04M-2.52587Upcoming EarningsMESOMesoblast1.5901 of 5 stars$9.74+6.0%N/A+298.4%$1.11B$5.90M0.0080News CoverageGap DownIMTXImmatics2.3143 of 5 stars$9.04-2.3%N/A-3.9%$1.08B$58.44M-10.16260Short Interest ↓CRGXCARGO Therapeutics1.7566 of 5 stars$21.98-1.7%N/A+8.5%$1.01BN/A-0.43116Earnings ReportAnalyst ForecastNews CoverageCGEMCullinan Therapeutics2.1817 of 5 stars$17.27+7.8%N/A+54.5%$1.00B$18.94M-6.0830Positive NewsHigh Trading VolumeLENZLENZ Therapeutics0.6755 of 5 stars$35.75+1.9%N/AN/A$983.16MN/A0.00N/A Related Companies and Tools Related Companies Tarsus Pharmaceuticals Alternatives Immunocore Alternatives BioCryst Pharmaceuticals Alternatives Novavax Alternatives Vir Biotechnology Alternatives Mesoblast Alternatives Immatics Alternatives CARGO Therapeutics Alternatives Cullinan Therapeutics Alternatives LENZ Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PRME) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRME Stock Alerts